Pfizer-Innovent $650M Cancer Drug Pact Signals China's Rise as Pharma Hub

Pfizer partnered with China's Innovent Biologics to co-develop twelve anticancer programs, with Pfizer contributing $650M and four programs, Innovent eight. This deepens Big Pharma's reliance on Chinese biotech for early-stage R&D, a trend that may accelerate despite geopolitical tensions. The deal underscores China's growing role in global drug innovation, though regulatory and IP risks remain.